A detailed history of Algert Global LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Algert Global LLC holds 28,310 shares of ACLX stock, worth $1.55 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
28,310
Previous 9,190 208.05%
Holding current value
$1.55 Million
Previous $510,000 286.08%
% of portfolio
0.08%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$51.85 - $73.49 $991,372 - $1.41 Million
19,120 Added 208.05%
28,310 $1.97 Million
Q4 2023

Feb 14, 2024

SELL
$31.75 - $57.99 $17,780 - $32,474
-560 Reduced 5.74%
9,190 $510,000
Q2 2023

Aug 14, 2023

SELL
$27.49 - $46.9 $271,381 - $462,996
-9,872 Reduced 50.31%
9,750 $308,000
Q1 2023

May 12, 2023

BUY
$26.92 - $33.94 $323,632 - $408,026
12,022 Added 158.18%
19,622 $605,000
Q4 2022

Feb 13, 2023

BUY
$18.99 - $33.0 $144,324 - $250,800
7,600 New
7,600 $235,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $2.4B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.